Reckitt Benckiser to spin out US pharma arm


Consumer health firm Reckitt–Benckiser plans to spin off its US pharmaceutical division, whose primary product is heroin-substitute Suboxone (buprenorphine and naloxone) for treating addiction.

Suboxone’s patent protection has expired, and generic competition is eroding the drug’s sales and market share. With Reckitt increasingly focusing on over-the-counter and consumer products, the company has decided that the best option is to divest the business as a separate company, specialising in addiction. Reckitt expects the spin-off to be completed in the next 12 months.


Related Content

Reckitt steps into Schiff deal

19 November 2012 Business

news image

Higher bid could sink Bayer's $1.2bn attempt to buy vitamins and nutritional supplements company

The pain killer

13 November 2013 Jobs Profile (Personal)

news image

Life is pretty painless working in Reckitt Benckiser's Nurofen team, Sarah Houlton learns

Most Read

Not all science is created equal

16 October 2014 Comments

news image

John Ioannidis explains why researchers should be curious about the differences between disciplines

MDMA

9 October 2014 Podcast | Compounds

news image

The drug that fuelled rave culture may yet be a treatment for PTSD. Hayley Simon introduces MDMA

Most Commented

Not all science is created equal

16 October 2014 Comments

news image

John Ioannidis explains why researchers should be curious about the differences between disciplines

MDMA

9 October 2014 Podcast | Compounds

news image

The drug that fuelled rave culture may yet be a treatment for PTSD. Hayley Simon introduces MDMA